Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

Table 1 Model inputs

	Estimates	Low	High	Source
Health state utilities	0.673	0.27	0.80	[16, 17]
Stable disease on oral therapy	0.653	0.26	0.78	[16, 17]
Stable disease on IV therapy	0.473	0.19	0.56	[16, 17]
Progressive disease	0			[16, 17]
Death
Cost of medical services and drugs (€)	2174.7	1627	3021	[12, 13]
Erlotinib 30 days supply (150 mg)	9.1/mg			[12, 13]
Docetaxel	0.2/mg			[12, 13]
Gemcitabine	368			[12, 13]
Hospitalization at home (day)	422			[12, 13]
Day-ward hospital	557.40			[12, 13]
G-CSF injection (per cycle)	220.53			[12, 13]
Erythropoietin (per injection)	2324			[15]
Palliative care after progression (per month)

ISSN: 1471-2407